Cocaine Hydrochloride

Offering timely insights on shifting drug use trends to inform targeted, life-saving strategies This is a transformative public-private partnership in service to the public health. We are honored to support CDC efforts to prevent drug overdoses and save lives.” — Millennium Health CEO Scott Walton SAN DIEGO, CA, UNITED STATES, April 21, 2026 / EINPresswire.com / -- Millennium Health announced today that it supplied the clinical urine drug testing (UDT) data underpinning the Centers for Disease Control and Prevention’s new public dashboard on U.S. drug-use trends. This new dashboard uses Millennium Health UDT data to report quarterly and six month, national and regional trends for fentanyl, heroin, cocaine, and methamphetamine use, as well as polysubstance use. This important public health tool is the result of years of collaborative effort between CDC and Millennium Health researchers to understand and optimize UDT data as a surveillance source. “This is a transformative public-private partnership in service to the public health,” said Millennium Health CEO Scott Walton. “We are honored to support CDC efforts to prevent drug overdoses and save lives.” Millennium Health, a leading drug testing company, processes thousands of urine drug tests daily from across the US. Trends in the percentage of specimens testing positive for the reported drugs strongly correlate with trends in fatal drug overdose deaths. “We strive to have the timeliest data about drugs that are driving overdose deaths. These data will have a profound impact on the nation’s ability to provide tailored and rapid interventions, ultimately preventing more overdose deaths,” said Grant Baldwin, PhD, Director of CDC’s Division of Overdose Prevention. In addition to the public release, the CDC will roll out the dashboard to state and local health departments to support local efforts to prevent and address overdose deaths. About Millennium Health Millennium Health is an accredited specialty laboratory with over 15 years of experience in drug testing. We provide objective information about patients’ recent use of prescription medications and/or illicit drugs which helps clinicians monitor and treat millions of Americans living with chronic pain, substance use disorders, mental health disorders or other health conditions. Our ability to monitor drug use trends allows us to alert clinicians, health agencies and others to real-time drug use changes to help inform more targeted drug overdose prevention and response strategies to save lives. Aaron Cohen Millennium Health +1 301-633-6773 PR@millenniumhealth.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of penetration testing as part of its upcoming FDA 510(k) submission. The testing identified no major vulnerabilities, verified the robustness of the Company's existing security infrastructure, and strengthened its regulatory submission to the FDA. In conjunction with the penetration testing, INBS implemented additional security upgrades to its drug testing technology. These upgrades include enhanced encrypted identification tags to ensure test integrity and improved firmware safeguards that allow only authorized updates and protect against cyber threats. "Successful completion of penetration testing is another key milestone in our FDA 510(k) submission process. This independent assessment identified no major security vulnerabilities, confirming the effectiveness of our security approach,” said Harry Simeonidis, President and CEO at INBS. “These new upgrades reflect our commitment to protecting donor data and implementing security measures that meet and exceed regulatory expectations, bolstering our upcoming 510(k) submission to the FDA." The penetration testing forms part of INBS's FDA 510(k) submission. By addressing security requirements early in the process, INBS is positioning its technology to meet evolving FDA guidance on medical device cybersecurity. If obtained, FDA clearance will open new revenue and expansion opportunities for the Company in the multi-billion-dollar U.S. drug screening market. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. For more information, visit:  Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact Intelligent Bio Solutions Inc. info@ibs.inc Investor & Media Contact Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@kcsa.com